One MedImmune Way
Gaithersburg,  MD  20878

United States
  • Booth: 14

AstraZeneca/MedImmune’s Approach to Immuno-Oncology (IO) is anchored by immunotherapies that have been designed to overcome anti-tumor immune suppression. Durvalumab, an anti-PD-L1 antibody, is being investigated in an extensive clinical trial program - as monotherapy or in combination with tremelimumab, our anti-CTLA-4 antibody, or a range of small targeted molecules - in multiple tumor types. We believe IO therapies will offer the potential for life-changing anti-cancer treatments.